Bei Wang

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 6

Top Topics

Early Breast Cancer

Acute Lymphoblastic Leukemia

Epidermal Growth Factor Receptor

Molecular Dynamics

Top Venues

Clinical and translational science

Cancer chemotherapy and pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Brendan Bender, Chi-Chung Li, Mathilde Marchand, David C Turner, Feifei Li, Shweta Vadhavkar, Bei Wang, Rong Deng, James Lu, Jin Yan Jin, Chunze Li, Shen Yin, Michael Wei, Pascal Chanu
Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma. Clinical and translational science 17 (6) (2024)
Brendan Bender, Chi-Chung Li, Mathilde Marchand, David C Turner, Feifei Li, Shweta Vadhavkar, Bei Wang, Rong Deng, James Lu, Jin Yan Jin, Chunze Li, Shen Yin, Michael Wei, Pascal Chanu
Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma. Clinical and translational science 17 (6) (2024)
Brendan Bender, Chi-Chung Li, Mathilde Marchand, David C Turner, Feifei Li, Shweta Vadhavkar, Bei Wang, Rong Deng, James Lu, Jin Yan Jin, Chunze Li, Shen Yin, Michael Wei, Pascal Chanu
Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma. Clinical and translational science 17 (6) (2024)
Brendan Bender, Chi-Chung Li, Mathilde Marchand, David C Turner, Feifei Li, Shweta Vadhavkar, Bei Wang, Rong Deng, James Lu, Jin Yan Jin, Chunze Li, Shen Yin, Michael Wei, Pascal Chanu
Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma. Clinical and translational science 17 (6) (2024)
Bei Wang, Rong Deng, Stefanie Hennig, Tanja Badovinac Crnjevic, Monika Kaewphluk, Matts Kågedal, Angelica L Quartino, Sandhya Girish, Chunze Li, Whitney P Kirschbrown
Correction to: Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study. Cancer chemotherapy and pharmacology (2021)
Bei Wang, Rong Deng, Stefanie Hennig, Tanja Badovinac Crnjevic, Monika Kaewphluk, Matts Kågedal, Angelica L Quartino, Sandhya Girish, Chunze Li, Whitney P Kirschbrown
Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study. Cancer chemotherapy and pharmacology 88 (3) (2021)